Sun, Huiying

Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures

Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes

Cited by 986

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 748

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 468

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 387

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 242

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine

Lung Cancer Treatments and MutationsHippo pathway signaling and YAP/TAZ

Cited by 177

SIRT2 functions as a histone delactylase and inhibits the proliferation and migration of neuroblastoma cells

Zu, H., Li, C., Dai, C., Pan, Y., Ding, C., Sun, H., Zhang, X., Yao, X., Zang, J., & Mo, X. (2022) · Cell Discovery

Sirtuins and Resveratrol in MedicineHistone Deacetylase Inhibitors Research

Cited by 163

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Nilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 146

Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population‐based retrospective cohort study

Nosyk, B., Sun, H., Evans, E., Marsh, D. C., Anglin, M. D., Hser, Y., & Anis, A. H. (2012) · Addiction

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 81